JAGUAR HEALTH, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- JAGUAR HEALTH, INC. stock issued during period, value, stock options exercised for the quarter ending 2022-09-30 was $1.00K, a 50.00% decline year-over-year.
- JAGUAR HEALTH, INC. stock issued during period, value, stock options exercised for the quarter ending 2021-12-31 was $0.00.
- JAGUAR HEALTH, INC. stock issued during period, value, stock options exercised for the quarter ending 2021-09-30 was $2.00K.
- JAGUAR HEALTH, INC. stock issued during period, value, stock options exercised for the quarter ending 2021-06-30 was $2.00K.
- JAGUAR HEALTH, INC. stock issued during period, value, stock options exercised for fiscal 2021 was $4.00K.
- JAGUAR HEALTH, INC. stock issued during period, value, stock options exercised for fiscal 2015 was $12.65K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2022-09-30 | $1.00K 10-Q · filed 2022-11-14 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $4.00K 10-K · filed 2023-03-24 |
| 2021-09-30 | $2.00K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $2.00K 10-Q · filed 2022-08-22 | |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-15 | $12.65K 10-K · filed 2017-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |